TVRD - Tvardi Therapeutics, Inc. Common Stock
| Day | 1m | 10m | 60m | PreMarket | Market | AfterHours | Gap |
|---|---|---|---|---|---|---|---|
| 6.91 -0.31 (-4.49%) | --- | -0.01 (-0.15%) | 0.07 (1.07%) | -0.1 (-1.45%) | -0.23 (-3.33%) | 0.02 (0.37%) | 0.02 (0.37%) |
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.
Category:
PHARMACEUTICAL PREPARATIONS
Market Period:
Closed
Earnings & Ratios
- Basic EPS:
- 0.51
- Diluted EPS:
- -1.0
- Basic P/E:
- 12.9412
- Diluted P/E:
- -6.6
- RSI(14) 1m:
- 78.57
- VWAP:
- 6.6
- RVol:
- 1.5849
Events
| Period | Kind | Movement | Occurred At |
|---|---|---|---|
| 1m | Price decrease 1m | 6.7 -0.09 (-1.33%) | Oct 15 15:37 |
| 1m | Price increase 1m | 6.68 +0.1 (+1.6%) | Oct 15 15:35 |
| 1m | Price decrease 1m | 6.59 -0.09 (-1.35%) | Oct 15 15:28 |
| 1m | Price increase 1m | 6.7 +0.07 (+1.09%) | Oct 15 15:24 |
| 1m | Price increase 1m | 6.65 +0.07 (+1.05%) | Oct 15 13:14 |